Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple... (rmation about Rebif(R) pleasevisit A HRE...)

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

Date:9/16/2008

rmation about Rebif(R), please visit http://www.mslifelines.com for prescribing information.

* The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. Full prescribing information for this product can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including oral cladribine, currently in Phase III and potentially the first oral therapy for MS, as well as several products in early stage development. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands s
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
2. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
3. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma

Post Your Comments:

(Date:12/14/2009)... 14 Seven leading cancer ... US Oncology Research participated in ... the 2009 San Antonio Breast ... at the Henry B. Gonzalez ... Texas . Fifteen others presented ...

(Date:12/14/2009)... The board of directors of Eli Lilly and Company ... for the first quarter of 2010 of $0.49 a ... dividend is payable March 10, 2010 to shareholders of ... February 12, 2010. ,, Lilly, a leading innovation-driven corporation, ... applying the latest research from its own worldwide laboratories ...

(Date:12/14/2009)... Medical Corporation (OTC Bulletin Board: CONX), a ... kits, and BG Medicine, Inc. (BGM), a ... a supply agreement whereby Corgenix will manufacture ... assay (ELISA) microtiter format exclusively for BG ... in the United States of the BGM ...

[0] US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium [0] Lilly Declares First-Quarter 2010 Dividend [0] Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)

... for ... From Chronic Pain, ALBUQUERQUE, New Mexico, March 31 ... life,announced today that the U.S. Food and Drug Administration (FDA) ... the United,States. The patented, high-tech medical device is intended to ...

... Ranexa(R) mechanism of action -, CHICAGO, March 31 ... that ranolazine significantly (p<0.001),shortened the QT interval of patients ... which is caused by a genetic mutation in the ... problems, including,sudden death. Ranolazine also shortened cardiac relaxation time ...

Other Medicine Technology:Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 2 Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2 Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3

Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder

(Date:12/14/2009)... activities like housework, gardening replaced tube watching , , MONDAY, ... 25 or 26 hours of television a week until ... cut his tube time in half. , During his ... each day, and not necessarily through strenuous exercise, although ... his newly freed time was spent reading and working ...

(Date:12/14/2009)... Marc Sedwitz Heads up 900-Member Physician Staff , ... ... La Jolla have elected Marc Sedwitz, MD, as the new chief ... as head of the 900-member physician team on Jan. 1, 2010. ... serve as medical staff liaison to Scripps La Jolla’s administrative staff ...

(Date:12/14/2009)... -- Skilled nursing facilities (SNFs) in Ohio are making ... deal with a 92 percent increase in the state-imposed ... $12.01 per bed per day, scheduled for December 15. ... pay an additional $17,520 to the state each month, ... $438,365 yearly. ,, Nearly 96 percent of skilled nursing ...

(Date:12/14/2009)... Critical to Stemming Tide of Tens of Thousands ... WASHINGTON, Dec. 14 Legislation approved by ... will be crucial in helping to reduce tens ... each year in the United States, the ... The provision was included in the FY ...

(Date:12/14/2009)... WASHINGTON, Dec. 14 The Hemophilia Federation ... ongoing labor issues involving the Teamsters Local 929 ... Jersey. The national blood system depends on skilled ... The blood is distilled into products such as ... von Willebrand disease. ,, The Division of ...

Breaking Medicine News(10 mins):Health News:Cutting TV Time Burns More Calories 2 Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2 Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3 Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2 Health News:HFA Voices Blood Safety Concerns 2

[0] Cutting TV Time Burns More Calories [1] New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla [1] Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts [0] NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange [0] HFA Voices Blood Safety Concerns

... Add Understanding Not Confusion, FOLSOM, Calif., Feb. 20 ... of California Walnut Commission: Given the state of the,national ... choices is clear. We welcome new independent nutrition rating ... packaging. While some fear,that this will be confusing, our ...

... a New Era of Clean Slumber and an Industry ... ... CleanRest(R), an industry,leading innovator that creates and develops products devoted to improving,the ... World,s Cleanest Pillow(TM)" featuring MicronOne(TM),technology. This news ends a year of tremendous ...

... Varian Medical,Systems (NYSE: VAR ) is ... RapidArc(TM) radiotherapy technology for faster and more,precise cancer ... more about a technology that makes it possible ... eight,times faster than is possible with conventional IMRT ...

... American Stroke Associations International Stroke Conference 2008 to be ... Convention Center in New Orleans, La. , This ... scientists and physicians engaged in research and treatment of ... United States. Nearly 4,000 attendees are expected. ...

... Racial Minorities, the Uninsured and,Medicare Patients, ... revealing,decreasing trends in cancer deaths in the ... in particular, highlight the remarkable benefits,of colorectal ... of these,tests is unrealized for many Americans, ...

... 19 On November 5, 2007, under increasing,government pressure, ... of its drug Trasylol after a Canadian clinical study,found ... of death than other drugs.,The Food and Drug Administration ... prevent excessive bleeding during heart bypass surgery,pending detailed review ...

Other Medicine News:Health News:Walnuts Rank High on New Nutrition Scales 2 Health News:Walnuts Rank High on New Nutrition Scales 3 Health News:CleanRest(R) Announces a Groundbreaking Invention, The World's Cleanest Pillow(TM) 2 Health News:CleanRest(R) Announces a Groundbreaking Invention, The World's Cleanest Pillow(TM) 3 Health News:Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments 2 Health News:Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments 3 Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 2 Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 3 Health News:U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer 4 Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 2 Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 3 Health News:Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes' 4

Walnuts Rank High on New Nutrition Scales CleanRest(R) Announces a Groundbreaking Invention, The World's Cleanest Pillow(TM)Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments ASA International Stroke Conference 2008 U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer Randone Trasylol Lawsuit Profiled on CBS' '60 Minutes'

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Dopamine, Plasma Donath Landsteiner DNA Double Stranded Antibody, IgG DNA Content/Cell Cycle Analysis, Colon

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple...(rmation about Rebif(R) pleasevisit A HRE...),Health